轉(zhuǎn)化性癌癥研究（Transl Cancer Res-TCR；印刷ISSN:2218-676X；在線ISSN 2219-6803；www.the tcr.org）是一個開放的、同行評審的期刊，由AME出版公司出版，發(fā)表了連接實驗室和臨床環(huán)境的新型研究調(diào)查結果，包括風險評估、細胞和分子。以提高癌癥患者臨床護理水平為總體目標，對人類癌癥進行定性、預防、檢測、診斷和治療。TCR將公布新的治療干預措施的實驗室研究以及評估癌癥新治療模式的臨床試驗。TCR的重點是原始的、同行評審的、基于科學的研究，該研究成功地將臨床醫(yī)學推向改善癌癥患者生活的目標。編輯和一個由科學家和臨床醫(yī)生科學家以及其他專家組成的國際咨詢小組將把TCR文章保持在高質(zhì)量標準。我們接受原創(chuàng)文章以及評論文章、社論和簡短文章。香港翻譯癌癥研究學會官方刊物。

Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; www.thetcr.org) is an Open Access, peer-reviewed journal, published by AME Publishing Company, publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. TCR will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving cancer patients lives. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles. The Official Publication of Society for Translational Cancer Research (STCR),Hong Kong